Cláudio Saddy Rodrigues Coy

Cláudio Saddy Rodrigues Coy

Auto-generated profile, based on publicly available information

Cláudio Saddy Rodrigues Coy

Universidade Estadual de Campinas, Brasil

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2018 in World Journal of Emergency Surgery
Verified
Journal Article
Open access
PDF file
MPMichele Pisano
Michele Pisano
LZLuigi Zorcolo
Luigi Zorcolo
CMCecilia Merli
Cecilia Merli
SCstefania cimbanassi
stefania cimbanassi
EPElia Poiasina
Elia Poiasina
LALuca Ansaloni
Luca Ansaloni
Obstruction and perforation due to colorectal cancer represent challenging matters in terms of diagnosis, life-saving strategies, obstruction resolution and oncologic challenge. The aims of the current paper are to update the previous WSES guidelines for the management of large bowel perforation and obstructive left colon carcinoma (OLCC) and to develop new guidelines on obstructive right colon carcinoma (ORCC). The literature was extensively queried for focused publication until December 2017. Precise analysis and grading of the literature has been performed by a working group formed by a pool of experts: the statements and literature review were presented, discussed and voted at the Consensus Conference of the 4th Congress of the World Society of Emergency Surgery (WSES) held in Campinas in May 2017. CT scan is the best imaging technique to evaluate large bowel obstruction and perforation. For OLCC, self-expandable metallic stent (SEMS), when available, offers interesting advantages as compared to emergency surgery; however, the positioning of SEMS for surgically treatable causes carries some long-term oncologic disadvantages, which are still under analysis. In the context of emergency surgery, resection and primary anastomosis (RPA) is preferable to Hartmann’s procedure, whenever the characteristics of the patient and the surgeon are permissive. Right-sided loop colostomy is preferable in rectal cancer, when preoperative therapies are predicted. With regards to the treatment of ORCC, right colectomy represents the procedure of choice; alternatives, such as internal bypass and loop ileostomy, are of limited value. Clinical scenarios in the case of perforation might be dramatic, especially in case of free faecal peritonitis. The importance of an appropriate balance between life-saving surgical procedures and respect of oncologic caveats must be stressed. In selected cases, a damage control approach may be required. Medical treatments including appropriate fluid resuscitation, early antibiotic treatment and management of co-existing medical conditions according to international guidelines must be delivered to all patients at presentation. The current guidelines offer an extensive overview of available evidence and a qualitative consensus regarding management of large bowel obstruction and perforation due to colorectal cancer.

24 July 2014 in Nutrition Journal
Verified
Journal Article
Open access
PDF file
DMDaniela Oliveira Magro
Daniela Oliveira Magro
LOLais Mariana R de Oliveira
Lais Mariana R de Oliveira
IBIsabela Bernasconi
Isabela Bernasconi
MRMarilia de Souza Ruela
Marilia de Souza Ruela
LCLaura Credidio
Laura Credidio
CCClaudio S R Coy
Claudio S R Coy
Constipation is a frequent complaint and the combination of a prebiotic and probiotics could have a potentially synergic effect on the intestinal transit. The present study therefore aims to investigate the combination of polydextrose (Litesse®), L. acidophilus NCFM® and B. lactis HN019 in a yogurt on intestinal transit in subjects who suffer from constipation.

8 September 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MIMarcello Imbrizi
Marcello Imbrizi
Fernando MagroFernando Magro
Fernando Magro
CCClaudio Saddy Rodrigues Coy
Claudio Saddy Rodrigues Coy
Inflammatory Bowel Diseases had their first peak in incidence in countries in North America, Europe, and Oceania and are currently experiencing a new acceleration in incidence, especially in Latin America and Asia. Despite technological advances, 90 years after the development of the first molecule for the treatment of IBD, we still do not have drugs that promote disease remission in a generalized way. We carried out a narrative review on therapeutic advances in the treatment of IBD, the mechanisms of action, and the challenges facing the therapeutic goals in the treatment of IBD. Salicylates are still used in the treatment of Ulcerative Colitis. Corticosteroids have an indication restricted to the period of therapeutic induction due to frequent adverse events, while technologies with less systemic action have been developed. Most immunomodulators showed a late onset of action, requiring a differentiated initial strategy to control the disease. New therapeutic perspectives emerged with biological therapy, initially with anti-TNF, followed by anti-integrins and anti-interleukins. Despite the different mechanisms of action, there are similarities between the general rates of effectiveness. These similar results were also evidenced in JAK inhibitors and S1p modulators, the last therapeutic classes approved for the treatment of IBD.

1 June 2019 in Arquivos de Gastroenterologia
Verified
Journal Article
Open access
PDF file
AAArlete Silva Acciari
Arlete Silva Acciari
Raquel Franco LealRaquel Franco Leal
Raquel Franco Leal
CCCláudio Saddy Rodrigues Coy
Cláudio Saddy Rodrigues Coy
CDCristiana Corrrêa Dias
Cristiana Corrrêa Dias
MAMaria de Lourdes Setsuko Ayrizono
Maria de Lourdes Setsuko Ayrizono
BACKGROUND: Crohn’s disease is chronic, requires prolonged treatment, affects the physical and psychosocial health of patients and may alter their routine, quality of life and well-being. Recent studies recommend monitoring the health of these patients considering physical, psychological and psychosocial aspects, because they are directly related to the disease activity. These studies highlight the relevance of patients’ emotional and behavioral conditions and suggest that the identification of the factors that influence the psychological well-being, resilience and Coping in these patients can favor the proper treatment. OBJECTIVE: To relate psychological well-being, resilience and Coping with social and clinical features of Crohn’s disease patients. METHODS: Prospective study including 104 patients with Crohn’s disease, both genders and mean age of 39 years. Standardized scales were used to assess and to relate psychological well-being, resilience and Coping with social and clinical variables. A questionnaire to characterize the sample and standardized scales in data collection (psychological well-being, resilience pillars and Coping strategies inventory - Folkman & Lazarus) were used. Descriptive analysis of data and statistics for comparison of results were performed. RESULTS: There were significant differences (P<0.05) showing better psychological well-being for male patients, those who without children, were not religious, were employed and were doing complementary activities in addition to clinical treatment. More resilience for the male gender, those who without children, were not religious, divorced, separated or widowed, that received some monthly income; who did not undergo surgery, had the first symptoms after 30 years old and who had complementary activity. There were also significant differences in the use of Coping: usually, women used more developed escape and avoidance strategies; single, married or in stable-union patients used more self-control; not religious used positive revaluation strategy; the ones who were employed showed more self-control and positive reassessment; the ones who had lower family income indicated that they used less the self-control; the ones who had higher family income used more positive re-evaluation; patients who were diagnosed with Crohn’s disease between the second decade of life showed to use mores more the positive reassessment strategy than those who were 20 years old or younger. CONCLUSION: Social aspects influenced psychological well-being, resilience and Coping in patients with Crohn’s disease more strongly than clinical aspects. It was possible to identify the profiles with better and worse psychological well-being, resilience and Coping of those who need more support, as well as to know the most used Coping strategies in the studied group.

1 September 2019 in Arquivos de Gastroenterologia
Verified
Journal Article
Open access
PDF file
Abel QuaresmaAbel Quaresma
Abel Quaresma
CCClaudio Saddy Rodrigues Coy
Claudio Saddy Rodrigues Coy
ADAderson Omar Mourão Cintra Damião
Aderson Omar Mourão Cintra Damião
GKGilaad Kaplan
Gilaad Kaplan
PKPaulo Kotze
Paulo Kotze
BACKGROUND: The introduction of anti-TNF agents represented a landmark in the management of both Crohn’s disease (CD) and ulcerative colitis (UC), with improved efficacy and safety when compared with conventional treatment. However, significant challenges still exist in Latin America to facilitate the access of biological agents for physicians and patients. OBJECTIVE: The aim of this review was to summarize current evidence on penetration of biological agents for CD and UC in Latin America. METHODS: Data are derived from a previous complete systematic review that explored different characteristics of inflammatory bowel diseases (IBD) in Latin America. The studies fully included in this previous systematic review which contained detailed descriptions of the percentage of use of biological agents in different cohorts throughout Latin American and Caribbean countries were included, and descriptive findings were compiled, describing CD and UC penetration of these drugs in different patient cohorts from different countries. RESULTS: From the 61 studies included in the original systematic review, only 19 included data of the percentage of patients treated with biological agents. Anti-TNF use in CD varied from 1.51% in Mexico up to 46.9% in Colombia, with most of the studies describing anti-TNF use in approximately 20%-40% of CD patients. On the other side, the frequency of the use of biologics was clearly lower in UC, varying from 0% in 2009 to up 16.2% in 2018, according to two different Mexican studies. Only two studies described the penetration of anti-TNF agents in IBD overall: 13.4% in a Colombian and 37.93% in a Brazilian study. No studies described percentage of use of new biologic agents (vedolizumab and ustekinumab). CONCLUSION: Penetration of anti-TNF agents in Latin America is comparable to the rest of the world in CD, but lower in UC. With the increase in the incidence and prevalence of IBD, specific strategies to increase access to anti-TNF agents in UC and new biological agents overall are warranted.

1 October 2019 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
MCMarina Moreira de Castro
Marina Moreira de Castro
Ligiana Pires CoronaLigiana Pires Corona
Ligiana Pires Corona
Lívia Bitencourt PascoalLívia Bitencourt Pascoal
Lívia Bitencourt Pascoal
BRBruno Lima Rodrigues
Bruno Lima Rodrigues
MAMaria de Lourdes Setsuko Ayrizono
Maria de Lourdes Setsuko Ayrizono
MMMarciane Milanski
Marciane Milanski